Press Release Archive
Press Releases
March 2022
February 2022
02.28.2022 Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 02.25.2022 FDA Accepts for Review Pfizer’s Supplemental Application for ABRILADA™ (adalimumab-afzb) Interchangeability 02.25.2022 Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment 02.24.2022 Covid-19 Pfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 through 17 Years of Age in the European Union 02.23.2022 CDC Advisory Committee on Immunization Practices Votes to Recommend TicoVac™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine, For Those at Risk of Virus Exposure 02.22.2022 Pfizer Statement on Results of Third Annual Pay Equity Study Among Colleagues Worldwide 02.22.2022 Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conference 02.15.2022 Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency 02.15.2022 European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults 02.14.2022 Partnerships Pfizer joins the Open Targets consortium 02.14.2022 Research Biohaven and Pfizer Announce Positive Top-Line Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.